Stock Analysis
- Japan
- /
- Life Sciences
- /
- TSE:4880
CellSource Second Quarter 2024 Earnings: EPS: JP¥7.58 (vs JP¥10.38 in 2Q 2023)
CellSource (TSE:4880) Second Quarter 2024 Results
Key Financial Results
- Revenue: JP¥1.11b (flat on 2Q 2023).
- Net income: JP¥150.0m (down 23% from 2Q 2023).
- Profit margin: 14% (down from 18% in 2Q 2023).
- EPS: JP¥7.58 (down from JP¥10.38 in 2Q 2023).
All figures shown in the chart above are for the trailing 12 month (TTM) period
CellSource Earnings Insights
Looking ahead, revenue is forecast to grow 15% p.a. on average during the next 3 years, compared to a 14% growth forecast for the Life Sciences industry in Asia.
Performance of the market in Japan.
The company's share price is broadly unchanged from a week ago.
Risk Analysis
Before you take the next step you should know about the 3 warning signs for CellSource (1 doesn't sit too well with us!) that we have uncovered.
Valuation is complex, but we're helping make it simple.
Find out whether CellSource is potentially over or undervalued by checking out our comprehensive analysis, which includes fair value estimates, risks and warnings, dividends, insider transactions and financial health.
View the Free AnalysisHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Valuation is complex, but we're helping make it simple.
Find out whether CellSource is potentially over or undervalued by checking out our comprehensive analysis, which includes fair value estimates, risks and warnings, dividends, insider transactions and financial health.
View the Free AnalysisHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com
About TSE:4880
CellSource
Engages in the regenerative medicine-related businesses in Japan.
Flawless balance sheet with moderate growth potential.